Recent advances on antimony(III/V) compounds with potential activity against tumor cells

Basit Öğe Kaydı
dc.authorid0000-0003-3164-0038
dc.authorid0000-0001-9556-6266
dc.authorid0000-0003-3264-2406
dc.authorid0000-0001-6727-2711
dc.authorscopusid6602925165
dc.authorscopusid36785856200
dc.authorscopusid46860923200
dc.authorscopusid6507202525
dc.authorscopusid7005826059
dc.authorwosidOzturk, Ibrahim Ismet/K-1352-2013
dc.authorwosidHadjikakou, Sotiris K./I-2909-2019
dc.authorwosidKourkoumelis, Nikolaos/B-8555-2009
dc.contributor.authorHadjikakou, Sotiris K.
dc.contributor.authorÖztürk, İbrahim İsmet
dc.contributor.authorBanti, Christina N.
dc.contributor.authorKourkoumelis, Nikolaos
dc.contributor.authorHadjiliadis, N.
dc.date.accessioned2022-05-11T14:30:53Z
dc.date.available2022-05-11T14:30:53Z
dc.date.issued2015
dc.departmentFakülteler, Fen Edebiyat Fakültesi, Kimya Bölümü
dc.description.abstractAntimony one of the heavier pnictogens, has been in medical use against microbes and parasites as well. Antimony-based drugs have been prescribed against leishmaniasis since the parasitic transmission of the tropical disease was understood in the beginning of the 20th century. The activity of arsenic against visceral leishmaniasis led to the synthesis of an array of arsenic-containing parasitic agents, among them the less toxic pentavalent antimonials: Stibosan, Neostibosan, and Ureastibamine. Other antimony drugs followed: sodium stibogluconate (Pentostam) and melglumine antimoniate (Glucantim or Glucantime); both continue to be in use today despite their toxic side effects and increasing loss in potency due to the growing resistance of the parasite against antimony. Antimony compounds and their therapeutic potentials are under consideration from many research groups, while a number of early reviews recording advances of antimony biomedical applications are also available. However, there are only few reports on the screening for antitumor potential of antimony compounds. This review focuses upon results obtained on the anti-proliferative activity of antimony compounds in the past years. This survey shows that antimony(III/V) complexes containing various types of ligands such as thiones, thiosemicarbazones, dithiocarbamates, carboxylic acids, or ketones, nitrogen donor ligands, exhibit selectivity against a variety of cancer cells. The role of the ligand type of the complex is elucidated within this review. The complexes and their biological activity are already reported elsewhere. However quantitative structure-activity relationship (QSAR) modeling studies have been carried out and they are reported for the first time here. (C) 2015 Elsevier Inc. All rights reserved.
dc.description.sponsorshipNational Scholarships Foundation of Greece (IKY); COST ActionEuropean Cooperation in Science and Technology (COST) [CM1105]
dc.description.sponsorshipCNB and SKH acknowledge (i) the National Scholarships Foundation of Greece (IKY) for the fellowship of excellence for post graduate studies in Greece Program-Siemens and (ii) the COST Action CM1105 Functional metal complexes that bind to biomolecules for the stimulating discussions.
dc.identifier.doi10.1016/j.jinorgbio.2015.06.006
dc.identifier.endpage305
dc.identifier.issn0162-0134
dc.identifier.issn1873-3344
dc.identifier.pmid26092367
dc.identifier.scopus2-s2.0-84951569670
dc.identifier.scopusqualityQ1
dc.identifier.startpage293
dc.identifier.urihttps://doi.org/10.1016/j.jinorgbio.2015.06.006
dc.identifier.urihttps://hdl.handle.net/20.500.11776/7207
dc.identifier.volume153
dc.identifier.wosWOS:000367563200034
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorÖztürk, İbrahim İsmet
dc.language.isoen
dc.publisherElsevier Science Inc
dc.relation.ispartofJournal of Inorganic Biochemistry
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectMetallotherapeutics
dc.subjectBioinorganic Chemistry
dc.subjectAntimony compounds
dc.subjectAntitumor activity
dc.subjectGUSAR
dc.subjectAntitumor Activities
dc.subjectCrystal-Structure
dc.subjectStructural-Characterization
dc.subjectComplexes
dc.subjectCytotoxicity
dc.subjectChloride
dc.subjectLigands
dc.subjectQsar
dc.subjectDerivatives
dc.subjectAcid
dc.titleRecent advances on antimony(III/V) compounds with potential activity against tumor cells
dc.typeReview Article

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
7207.pdf
Boyut:
1.5 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Fen Edebiyat Fakültesi Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu